The pile of discarded biotech R&D programs is getting bigger and bigger. Hutchmed, NightHawk Biosciences and NexImmune are the latest companies to add to the list, tossing out programs yesterday in ...

In vivo studies are an essential component of biopharmaceutical R&D that help teams understand drug pharmacology, safety, and toxicology. They sit on the critical path to bringing new drugs into the ...

Incyte is whittling down its R&D pipeline, scrapping six discovery programs—one in a rare form of anemia and five in various cancers—to focus on eight remaining programs. The Jakafi maker’s remaining ...

There are very few companies that lack innovation programs. Innovation programs are often bigger than innovation projects and will house more than one innovation project. There are many different ...

Biogen (NASDAQ:BIIB) stock is trading in the red premarket Tuesday after the company said it is discontinuing certain drug programs amid reporting its Q1 results, which beat estimates. The company has ...